LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of the formula

in which

A represents a radical

in which

X represents N or C-H,

Y represents N-R⁷, O or S

in which

 R^7 represents hydrogen, benzyl, phenyl, $(C_1\text{-}C_6)$ -alkyl or $(C_3\text{-}C_8)$ -cycloalkyl,

where alkyl and cycloalkyl for their part may be substituted by fluorine, hydroxyl, amino, carboxyl, (C_1-C_6) -alkoxy, (C_1-C_6) -alkylamino or morpholinyl,

- Z represents N or C-H,
- R^6 represents hydrogen, halogen, trifluoromethyl, (C₁-C₆)-alkylamino or W- R^7 ,

in which

W represents NH, O or a bond,

R⁷ is as defined above

and

* denotes the point of attachment to the phenolic oxygen,

R¹ and R² independently of one another represent hydrogen, halogen or cyano,

R³ and R⁴ independently of one another represent hydrogen, fluorine or chlorine,

R⁵ represents a radical selected from the group consisting of:

hydrogen, hydroxyl, halogen, trifluoromethyl,

 (C_3-C_8) -cycloalkyl, (C_1-C_6) -alkyl, (C_1-C_6) -alkoxy,

where cycloalkyl, alkyl and alkoxy for their part may be substituted by hydroxyl, carboxyl, (C_1-C_6) -alkoxy, (C_1-C_6) -alkoxycarbonyl, (C_6-C_{10}) -aryl, NR^8R^9 or $C(=O)NR^8R^9$,

Docket No.: 69040(54716)

in which

 R^8 and R^9 independently of one another represent hydrogen, (C₁-C₈)-alkyl, optionally (C₁-C₆)-alkyl-substituted (C₃-C₆)-cycloalkyl, optionally halogen-substituted (C₆-C₁₀)-aryl or 5- to 10-membered heteroaryl

or

R⁸ and R⁹ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further heteroatom O or N in the ring and which may be substituted by (C₁-C₆)-alkyl, (C₁-C₆)-alkanoyl or (C₁-C₆)-alkoxycarbonyl,

 (C_6-C_{10}) -aryl, (C_6-C_{10}) -aryloxy, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heterocyclyl which is attached via a carbon atom,

where aryl, aryloxy, heteroaryl, heteroaryloxy and heterocyclyl for their part may be substituted by halogen, cyano, nitro, carboxyl, amino, trifluoromethyl, optionally hydroxyl-substituted (C_1 - C_6)-alkyl, (C_1 - C_6)-alkylamino, (C_1 - C_6)-alkanoyl, (C_1 - C_6)-alkoxycarbonyl, (C_1 - C_6)-alkanoylamino or 5- or 6-membered heterocyclyl,

 $NR^{10}R^{11}$

in which

 R^{10} and R^{11} independently of one another represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, (C₆-C₁₀)-aryl or 5- to 10-membered heteroaryl,

Docket No.: 69040(54716)

where alkyl and cycloalkyl for their part may be substituted by hydroxyl, (C_1-C_6) -alkoxy, (C_6-C_{10}) -aryl, 5- to 10-membered heteroaryl or NR¹⁵R¹⁶,

in which

 R^{15} and R^{16} independently of one another represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, (C₆-C₁₀)-aryl or 5- or 6-membered heteroaryl

or

R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further heteroatom O or N in the ring and which may be substituted by (C₁-C₆)-alkyl, (C₁-C₆)-alkanoyl or (C₁-C₆)-alkoxycarbonyl,

and

aryl and heteroaryl for their part may be substituted by halogen, hydroxyl, amino, cyano, trifluoromethyl, (C_1-C_6) -alkyl, (C_1-C_6) -alkylamino or (C_1-C_6) -alkanoylamino,

or

R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle which may contain a further heteroatom O or N in the ring and which may be substituted by fluorine, hydroxyl, carboxyl, 5- to 7-membered heterocyclyl which may contain one or two further heteroatoms N and/or O in the ring and which for its part may be substituted by (C₁-C₄)-alkyl or (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkoxy, optionally hydroxyl-, (C₁-C₄)-alkoxycarbonyl, respectively.

Docket No.: 69040(54716)

where

 R^{12} and R^{13} independently of one another represent hydrogen, $(C_1\text{-}C_6)\text{-alkyl}, (C_1\text{-}C_4)\text{-alkoxycarbonyl}, (C_3\text{-}C_8)\text{-cycloalkyl}$ or $(C_1\text{-}C_4)\text{-alkanoyl}$

or

R¹² and R¹³ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further heteroatom O or N in the ring and which may be substituted by (C₁-C₆)-alkyl, (C₁-C₆)-alkanoyl or (C₁-C₆)-alkoxycarbonyl,

and

 R^{17} and R^{18} independently of one another represent hydrogen, optionally hydroxyl-substituted (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, (C₆-C₁₀)-aryl or 5- or 6-membered heteroaryl

or

R¹⁷ and R¹⁸ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may

Application No. 10/531,889 Reply to Office Action of August 9, 2007

contain a further heteroatom O or N in the ring and which may be substituted by (C_1-C_6) -alkyl, (C_1-C_6) -alkanoyl or (C_1-C_6) -alkoxycarbonyl,

Docket No.: 69040(54716)

or

R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached form a 7- to 12-membered bicyclic or tricyclic heterocycle which is fused or spirocyclic and which may have one or two further heteroatoms from the group consisting of N and O in the ring and which may be substituted by fluorine, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkanoyl or benzyl,

and $C(=O)R^{14}$,

in which

R¹⁴ represents (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino or a 5- to 10membered mono- or bicyclic heterocycle which is attached via a nitrogen atom, which is fused or spirocyclic and which may have one or two further heteroatoms from the group consisting of N and O in the ring,

where alkylamino for its part may be substituted by a 5- or 6-membered heterocycle,

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

2. (Original) The compound as claimed in claim 1

in which

A represents a radical

in which

R⁶ represents hydrogen, (C₁-C₄)-alkyl or NH-R⁷,

R⁷ represents hydrogen or (C₁-C₄)-alkyl

and

* denotes the point of attachment to the phenolic oxygen,

R¹ and R² independently of one another represent hydrogen, fluorine or chlorine,

R³ and R⁴ independently of one another represent hydrogen or fluorine,

R⁵ represents a radical selected from the group consisting of:

hydrogen, chlorine, (C₃-C₈)-cycloalkyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy,

where alkyl and alkoxy for their part may be substituted by hydroxyl, carboxyl, (C_1-C_4) -alkoxy, (C_1-C_4) -alkoxycarbonyl, NR^8R^9 or $C(=O)NR^8R^9$,

in which

 R^8 and R^9 independently of one another represent hydrogen, (C₁-C₈)-alkyl, optionally (C₁-C₄)-alkyl-substituted (C₃-C₆)-cycloalkyl, optionally halogen-substituted phenyl or 5- or 6-membered heteroaryl

Docket No.: 69040(54716)

or

R⁸ and R⁹ together with the nitrogen atom to which they are attached form a morpholine, piperazine, piperidine or pyrrolidine ring, where the rings for their part may be substituted by (C₁-C₄)-alkyl,

 (C_6-C_{10}) -aryl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocyclyl which is attached via a carbon atom,

where aryl, heteroaryl and heterocyclyl for their part may be substituted by halogen, cyano, nitro, carboxyl, amino, trifluoromethyl, optionally hydroxyl-substituted (C_1 - C_4)-alkyl, (C_1 - C_4)-alkoxy, (C_1 - C_4)-alkylamino, (C_1 - C_4)-alkanoyl, (C_1 - C_4)-alkoxycarbonyl, (C_1 - C_4)-alkoxycarbonylamino or 6-membered heterocyclyl,

Docket No.: 69040(54716)

 $NR^{10}R^{11}$

in which

R¹⁰ and R¹¹ independently of one another represent hydrogen, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, phenyl or 5- or 6-membered heteroaryl,

where alkyl and cycloalkyl for their part may be substituted by hydroxyl, (C_1-C_4) -alkoxy, phenyl, 5- or 6-membered heteroaryl or $NR^{15}R^{16}$.

in which

R¹⁵ and R¹⁶ independently of one another represent hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl, phenyl or 5- or 6-membered heteroaryl

or

R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form a morpholine, piperazine, piperidine or pyrrolidine ring, where the rings for their part may be substituted by (C₁-C₄)-alkyl,

and

phenyl and heteroaryl for their part may be substituted by fluorine, chlorine, hydroxyl, amino, cyano, trifluoromethyl, (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, (C_1-C_4) -alkylamino or (C_1-C_4) -alkanoylamino,

Docket No.: 69040(54716)

or

R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle which may contain a further heteroatom O or N in the ring and which may be substituted by fluorine, hydroxyl, carboxyl, 5- to 7-membered heterocyclyl which may contain one or two further heteroatoms N and/or O in the ring and which for its part may be substituted by (C₁-C₄)-alkyl or (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkoxy, optionally hydroxyl-, (C₁-C₄)-alkoxy- or NR¹⁷R¹⁸-substituted (C₁-C₄)-alkyl, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkoxycarbonyl or NR¹²R¹³,

where

 R^{12} and R^{13} independently of one another represent hydrogen or (C_1-C_4) -alkyl

or

R¹² and R¹³ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further heteroatom O or N in the ring and which may be substituted by (C₁-C₆)-alkyl, (C₁-C₆)-alkanoyl or (C₁-C₆)-alkoxycarbonyl,

and

 R^{17} and R^{18} independently of one another represent hydrogen, optionally hydroxyl-substituted (C₁-C₄)-alkyl or phenyl

Docket No.: 69040(54716)

or

 R^{17} and R^{18} together with the nitrogen atom to which they are attached form a pyrrolidine ring,

or

R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached form a 7- to 12-membered bicyclic or tricyclic heterocycle which is fused or spirocyclic, which may have one or two further heteroatoms from the group consisting of N and O in the ring and which may be substituted by (C₁-C₄)-alkyl, (C₁-C₄)-alkovycarbonyl, (C₁-C₄)-alkanoyl or benzyl,

and C(=O)R14

in which

R¹⁴ represents (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino or a 5- to 10membered mono- or bicyclic heterocycle which is attached via a nitrogen atom, which is fused or spirocyclic and which may have one or two further heteroatoms from the group consisting of N and O in the ring,

where alkylamino for its part may be substituted by a 5- or 6-membered heterocyclyl,

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

3. (Previously presented) The compound as claimed in claim 1

in which

A represents a radical

$$R^6$$
 or R^6

in which

R⁶ represents hydrogen or methyl

and

* denotes the point of attachment to the phenolic oxygen,

R¹ and R² independently of one another represent hydrogen, fluorine or chlorine,

R³ and R⁴ represent hydrogen,

R⁵ represents a radical selected from the group consisting of:

hydrogen, chlorine, cyclohexyl, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy,

where alkyl and alkoxy for their part may be substituted by hydroxyl, carboxyl, (C_1-C_4) -alkoxy, methyloxycarbonyl, ethyloxycarbonyl, NR^8R^9 or $C(=O)NR^8R^9$,

in which

R⁸ and R⁹ independently of one another represent hydrogen, (C₁-C₈)-alkyl, cyclopropyl, optionally methyl-substituted cyclopentyl or optionally fluorine-substituted phenyl

Docket No.: 69040(54716)

or

R⁸ and R⁹ together with the nitrogen atom to which they are attached form a piperidine, 2-methylpiperidine or 2,6-dimethylpiperidine ring,

phenyl, pyridyl, pyrrolyl, piperidin-3-yl, piperidin-4-yl, pyrrolidin-2-yl,

where phenyl, pyridyl and pyrrolyl for their part may be substituted by fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, methyl, hydroxymethyl, methoxy, dimethylamino or morpholinyl,

and

piperidin-3-yl, piperidin-4-yl and pyrrolidin-2-yl for their part may be substituted by methyl, ethyl, n-propyl, isopropyl, methylcarbonyl or ethylcarbonyl,

 $NR^{10}R^{11}$

in which

R¹⁰ and R¹¹ independently of one another represent hydrogen, (C₁-C₄)-alkyl, 3-hydroxypropyl, 2-hydroxycyclohexyl, 2-aminocyclohexyl, phenyl, pyridyl or pyrazolyl,

where phenyl and pyridyl for their part may be substituted by chlorine, hydroxyl, amino, cyano, methyl or methoxy,

or

R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached form a piperazine, 3-methylpiperazine, 3,5-dimethylpiperazine, 4-isobutylpiperazine, morpholine, pyrrolidine, 3-aminopyrrolidine, 3-methylaminopyrrolidine, 3-(*N*,*N*-dimethylamino)pyrrolidine, 2-aminomethylpyrrolidine, 3-hydroxypyrrolidine, 2-hydroxymethylpyrrolidine or 2-methoxymethylpyrrolidine ring or a radical

in which

* denotes the point of attachment to the pyrimidine ring,

and $C(=O)R^{14}$

in which

R¹⁴ represents methoxy, piperidinyl-N-ethylamino, piperidinyl or piperazinyl,

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

- 4. (Original) A process for preparing compounds as defined in claim 1, characterized in that either
 - [A] compounds of the formula (II)

$$A \xrightarrow{R^{1}} R^{4}$$

$$R^{2} \xrightarrow{R^{3}} N \xrightarrow{H_{2}N} N \xrightarrow{CI} (II),$$

in which

 A, R^1, R^2, R^3 and R^4 are as defined in claim 1

are reacted with compounds of the formula (III)

$$R^{5}$$
 X^{1} (III),

Docket No.: 69040(54716)

in which

R⁵ is as defined in claim 1 and

X¹ represents hydrogen, B(OH)₂ or a boronic acid ester such as

or

[B] compounds of the formula (IV)

$$H_2N$$
 N R^5 $(IV),$

in which

R⁵ is as defined in claim 1

are reacted with compounds of the formula (V)

in which

A, R¹, R², R³ and R⁴ are as defined in claim 1.

- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Previously presented) A method for the treatment and/or prophylaxis of cardiovascular disorders wherein a cardiovascularly effective amount of a compound as defined in claim 1 is used.

Docket No.: 69040(54716)

- 9. (Previously presented) A pharmaceutical composition comprising a compound as defined in claim 1 and a further active compound.
- 10. (Previously presented) A pharmaceutical composition comprising a compound as defined in claim 1 in combination with an inert nontoxic pharmaceutically acceptable auxiliary.
- 11. (Previously presented) The method of claim 8, wherein the cardiovascular disorder is erectile dysfunction.